Vascular endothelial growth factor

European Journal of Cancer Part A

Volumn 32, Issue 14, 1996, Pages 2413-2422

  Ferrara, N ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL CELL GROWTH FACTOR;

ANGIOGENESIS; BREAST CARCINOMA; CELL PROLIFERATION; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; METASTASIS; PRIORITY JOURNAL; REVIEW;

EID: 0030500444     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00387-5     Document Type: Article

References (132)

1. 1. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992 267, 10931-10934.
2. 2. Garner. A. Vascular diseases. In Garner A, Klintworth GK, eds. Pathobiology of Occular Disease. A Dynamic Approach. 2nd Edition, New York, Marcel Dekker, 1994, 1625-1710.
3. 3. Weidner N, Semple P, Welch W, Folkman J. Tumor angiogenesis and metastasis. Correlation in invasive breast carcinoma. N Engl J Med 1991, 324, 1-6.
4. 4. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent progonostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992, 84, 1875-1888.
5. 5. Wakui S, Furusato M, Sasaki H, et al. Tumor angiogenesis in prostatic carcinoma with and without bone metastasis: a morphometric study. J Pathol 1992, 168, 257-262.
6. 6. Macchiarini P, Fontanini G, Hardin MJ, Squartini F, Angeletti CA. Relation of neovascularization to metastasis of non-small cell lung carcinoma. Lancet 1992, 340, 145-146.
7. 7. Smith-McCune KS, Weidner N. Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Res 1994, 54, 804-808.
8. 8. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219, 983-985.
9. 9. Dvorak HF. Tumours: wounds that do not heal. Similarity between tumor stroma generation and wound healing. N Engl J Med 1986, 315, 1650-1658.
10. 10. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989, 161, 851-859.
11. 11. Ploüet J, Schilling J, Gospodarowicz D. Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT20 cells. EMBO J 1989, 8, 3801-3807.
12. 12. Leung DW, Cachianes G, Kuang W-J, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246, 1306-1309.
13. 13. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT. Vascular permeability factor, an endothelial cell mitogen related to platelet derived growth factor. Science 1989, 246, 1309-1312.
14. 14. Conn G, Bayne M, Soderman L, et al. Amino acid and cDNA sequence of a vascular endothelial cell mitogen homologous to platelet-derived growth factor. Proc Natl Acad Sci USA 1990, 87, 2628-2632.
15. 15. Ferrara N. Vascular endothelial growth factor. Trends Cardiovasc Med 1993, 3, 244-250.
16. 16. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996, 380, 435-439.
17. 17. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996, 380, 439-442.
18. 18. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362, 841-844.
19. 19. Aiello LP, Avery R, Arrigg R, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994, 331, 1480-1487.
20. 20. Pearlman JD, Hibberd MG, Chuang ML, et al. Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis. Nature Medicine 1995, 1, 1085-1089.
21. 21. Takeshita S, Zhung L, Brogi E, et al. Therapeutic angiogenesis: a single intra-arterial bolus of vascular endothelial growth factor augments collateral vessel formation in a rabbit ischemic hindlimb model. J Clin Invest 1994, 93, 662-670.
22. 165 in patient with ischaemic limb. Lancet 1996, 348, 370-374.
23. 23. Pepper MS, Wasi S, Ferrara N, Orci L, Montesano R. In vitro angiogenic and proteolytic properties of bovine lymphatic endothelial cells. Exp Cell Res 1994, 210, 298-305.
24. 24. Jakeman LB, Winer J, Bennett GL, Altar CA, Ferrara N. Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rate tissues. J Clin Invest 1992, 89, 244-253.
25. 25. Jakeman LB, Armanini M, Phillips HS, Ferrara N. Developmental expression of binding sites and mRNA for vascular endothelial growth factor suggests a role for this protein in vasculogenesis and angiogenesis. Endocrinology 1993, 133, 848-859.
26. 26. Pepper MS, Ferrara N, Orci L, Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 1992, 189, 824-831.
27. 27. Nicosia RF, Nicosia SV, Smith M. Vascular endothelial growth factor, platelet-derived growth factor and insulin-like growth factor-1 promote rat aortic angiogenesis in vitro. Am J Pathol 1995, 145, 1023-1029.
28. 165) stimulates direct angiogenesis in the rabbit cornea. In Vivo 1995, 8, 961-965.
29. 29. Tolentino JM, Miller JW, Gragoudas ES, Chatzistefanou K, Ferrara N, Adamis AP. VEGF is sufficient to produce iris neovascularization and neovascular glaucoma in a non-human primate. Arch Ophthalmology 1996, 114, 964-970.
30. 30. Connolly DT, Heuvelman DM, Nelson R, et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989, 84, 1470-1478.
31. 31. Pepper MS, Ferrara N, Orci L, Montesano R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor type 1 in microvascular endothelial cells. Biochem Biophys Res Commun 1991, 181, 902-908.
32. 32. Unemori E, Ferrara N, Bauer EA, Amento EP. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol 1992, 153, 557-562.
33. 33. Mandriota S, Montesano R, Orci L, et al. Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J Biol Chem 1995, 270, 9709-9716.
34. 34. Roberts WG, Palade G. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 1995, 108, 2369-2379.
35. 35. Ku DD, Zaleski JK, Liu S, Brock T. Vascular endothelial growth factor induces EDRF-dependent relaxation of coronary arteries. Am J Physiol 1993, 265, H586-592.
36. 36. Yang R, Thomas GR, Bunting S, et al. Effects of VEGF on hemodynamics and cardiac performance. J Cardiovasc Pharmacol 1996, 27, 838-844.
37. 37. Tisher E, Mitchell R, Hartmann T, et al. The human gene for vascular endothelial growth factor. J Biol Chem 1991, 266, 11947-11954.
38. 38. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 1991, 5, 1806-1814.
39. 39. Vincenti V, Cassano C, Rocchi M, Persico G. Assignment of the vascular endothelial growth factor gene to the humam chromosome 6p21.3. Circulation 1996, 93, 1493-1495.
40. 40. Shima DT, Kuroki M, Deutsch U, Ng Y-S, Adamis AP, D'Amore PA. The mouse gene for vascular endothelial growth factor. J Biol Chem 1996, 271, 3877-3883.
41. 41. Levy AP, Levy NS, Wegner S, Goldberg MA. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 1995, 270, 13333-13340.
42. 42. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocrinol Rev 1992, 13, 18-32.
43. 43. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 1992, 267, 26031-26037.
44. 44. Park JE, Keller G-A, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms. Differential deposition into the subepithelial extracellular matrix and bioactivity of ECM-bound VEGF. Mol Biol Cell 1993, 4, 1317-1326.
45. 45. Rifkin DB, Moscatelli D, Bizik J, et al. Growth factor control of extracellular proteolysis. Cell Differ Devel 1990, 32, 313-318.
46. 46. Keyt B, Berleau L, Nguyen H, et al. The carboxyl-terminal domain (111-165) of VEGF is critical for mitogenic potency. J Biol Chem 1996, 271, 7788-7795.
47. 47. Shweioki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359, 843-845.
48. 48. Shima DT, Adamis AP, Ferrara N, et al. Hypoxic induction of vascular endothelial cell growth factors in the retina: identification and characterization of vascular endothelial growth factor (VEGF) as the sole mitogen. Mol Med 1995, 2, 64-71.
49. 49. Brogi E, Wu T, Namiki A, Isner JM. Indirect angiogenic cytokines upregulate VEGF and bFGF expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation 1994, 90, 649-652.
50. 50. Goldberg MA, Schneider TJ. Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J Biol Chem 1994, 269, 4355-4361.
51. 51. Stone J, Itin A, Alon T, et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression in neuroglia. J Neurosci 1995, 15, 4738-4747.
52. 52. Liu Y, Cox SR, Morita T, Kourembanas S. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Cir Res 1995, 77, 638-643.
53. 53. Madan A, Curtin PT. A 24-base pair sequence 3′ to the human erythropoietin contains a hypoxia-responsive transcription enhancer. Proc Natl Acad Sci USA 1993, 90, 3928-3932.
54. 2 tension. Proc Natl Acad Sci USA 1995, 92, 5510-5514.
55. 2 receptors and elevation of cAMP in retinal microvascular pericytes and endothelial cells. Invest Ophthalmol Vis Sci, in press.
56. 56. Mukhopadhyay D, Tsilokas L, Zhou X-M, Foster D, Brugge JS, Sukhatme VP. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 1995, 375, 577-581.
57. 57. Ikeda E, Achen MG, Breier G, Risau W. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 1995, 270, 19761-19766.
58. 58. Stein I, Neeman M, Shweiki D, Itin A, Keshet E. Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes. Mol Cell Biol 1995, 15, 5363-5368.
59. 59. Frank S, Hubner G, Breier G, Longaker MT, Greenhalgh DG, Werner S. Regulation of VEGF expression in cultured keratinocytes. Implications for normal and impaired wound healing. J Biol Chem 1995, 270, 12607-12613.
60. 60. Pertovaara L, Kaipainen A, Mustonen T, et al. Vascular endothelial growth factor is induced in response to transforming growth factor-β in fibroblastic and epithelial cells. J Biol Chem 1994, 269, 6271-6274.
61. 61. Li J, Perrella MA, Tsai JC, et al. Induction of vascular endothelial growth factor gene expression by interleukin-1 beta in rat aortic smooth muscle cells. J Biol Chem 1995, 270, 308-312.
62. 62. Ben-Av P, Crofford LJ, Wilder RL, H1a T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett 1995, 372, 83-87.
63. 63. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996, 271, 736-741.
64. 64. Claffey KP, Wilkinson WO, Spiegelman BM. Vascular endothelial growth factor. Regulation by cell differentiation and activated second messenger pathways. J Biol Chem 1992, 267, 16317-16322.
65. 65. Kieser A, Weich H, Brandner G, Marme D, Kolch W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 1994, 9, 963-969.
66. 66. Rak J, Mitsuhashi Y, Bayko L, et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995, 55, 4575-4580.
67. 67. Grugel S, Finkenzeller G, Weindel K, Barleon B, Marme D. Both v-Ha-Ras and v-Raf stimulate expression of vascular endothelial growth factor in NIH 3T3 cells. J Biol Chem 1995, 270, 25915-25919.
68. 68. Mukhopadhyay D, Tsiokas L, Sukhatme VP. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res 1995, 55, 6161-6165.
69. 69. deVries C, Escobedo JA, Ueno H, Houck KA, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992, 255, 989-991.
70. 70. Terman BI, Vermazen MD, Carrion ME, et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial growth factor. Biochem Biophys Res Commun 1992, 34, 1578-1586.
71. 71. Shibuya M, Yamaguchi S, Yamane A, et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase (flt) closely related to the fms family. Oncogene 1990, 8, 519-527.
72. 72. Matthews W, Jordan CT, Gavin M, Jenkins NA, Copeland NG, Lemischka IR. A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. Proc Natl Acad Sci USA 1991, 88, 9026-9030.
73. 73. Quinn T, Peters KG, deVries C, Ferrara N, Williams LT. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc Natl Acad Sci USA 1993, 90, 7533-7537.
74. 74. Millauer B, Wizigmann-Voos S, Schnurch H, et al. High affinity binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993, 72, 835-846.
75. 75. Kendell RL, Thomas KA. Inhibition of vascular endothelial growth factor by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 1993, 90, 10705-10709.
76. 76. Davis-Smyth T, Chen H, Park J, Presta L, Ferrara N. The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade. EMBO J 1996, 15, 4919-4927.
77. 77. Guo D, Jia Q, Song HY, Warren RS, Donner DB. Vascular endothelial growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. J Biol Chem 1995, 270, 6729-6733.
78. 78. Waltenberger J, Clasesson-Welsh L, Siegbahn A, Shibuya M, Heldin C-H. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994, 269, 26988-26995.
79. 79. Seetharam L, Gotoh N, Maru Y, Neufeld G, Yamaguchi S, Shibuya M. A unique signal transduction pathway for the FLT tyrosine kinase, a receptor for vascular endothelial growth factor. Oncogene 1995, 10, 135-147.
80. 80. Park JE, Chen H, Winer J, Houck K, Ferrara N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 1994, 269, 25646-25654.
81. 81. Keyt B, Nguyen H, Berleau L, Duarte C, Park J, Chen H, Ferrara N. Identification of VEGF determinants for binding Flt-1 and KDR receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis. J Biol Chem 1996, 271, 5638-5646.
82. 82. Morishita K, Johnson DE, Williams LT. A novel promoter for vascular endothelial growth factor receptor (flt-1) that confers endothelial-specific gene expression. J Biol Chem 1995, 270, 27948-27953.
83. 83. Tuder RM, Flook BE, Voelkel NF. Increased gene expression of VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or chronic hypoxia. J Clin Invest 1995, 95, 1798-1807.
84. 84. Thieme H, Aiello LP, Ferrara N, King GL. Comparative analysis of VEGF receptors on retinal and aortic endothelial cells. Diabetes 1995, 44, 98-103.
85. 2 receptors in retinal capillary endothelial cells. Invest Opthalmol Vis Sci 1996, 37, 1311-1321.
86. 86. Brogi E, Schatteman G, Wu T, et al. Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression. J Clin Invest 1996, 97, 469-476.
87. 87. Patterson C, Perrella MA, Endege WO, Yoshizumi M, Lee M-E, Haber E. Downregulation of vascular endothelial growth factor receptors by tumor necrosis factor-α in cultured human vascular endothelial cells. J Clin Invest 1996, 98, 4900-4960.
88. 88. Mandriota SJ, Menoud PA, Pepper MS. Transforming growth factor beta 1 down-regulates vascular endothelial growth factor receptor 2/flk-1 expression in vascular endothelial cells. J Biol Chem 1996, 271, 11500-11505.
89. 89. Fong G-H, Rassant J, Gertenstein M, Breitman M. Role of Flt-1 receptor tyrosine kinase in regulation of assembly of vascular endothelium. Nature 1995, 376, 66-67.
90. 90. Shalabi F, Rossant J, Yamaguchi TP, et al. Failure of blood island formation and vasculogenesis in Flk-1 deficient mice. Nature 1995, 376, 62-66.
91. 91. Brandon EP, Idzerda RL, McKnight GS. Targeting the mouse genome: a compendium of knockouts (part III). Curr Biol 1995, 5, 635-654.
92. 92. Mattern J, Koomagi R, Voom M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carinoma. Br J Cancer 1996, 73, 931-934.
93. 93. Viglietto G, Maglione D, Rambaldi M, et al. Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 1995, 11, 1569-1579.
94. 94. Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Human Pathol 1995, 26, 86-91.
95. 95. Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 1993, 53, 4727-4735.
96. 96. Suzuki K, Hayashi N, Miyamoto Y, et al. Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res 1996, 56, 3004-3009.
97. 97. Brown LF, Berse B, Jackman RW, et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 1993, 143, 1255-1262.
98. 98. Olson TA, Mohanraj D, Carson LF, Ramakrishnan S. Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res 1994, 54, 276-280.
99. 99. Guidi AJ, Abu-Jawdeh G, Berse B, et al. Vascular permeability factor (vascular endotheilal growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst 1995, 87, 12137-12145.
100. 100. Hashimoto M, Ohsawa M, Ohnishi A, et al. Expression of vascular endothelial growth factor and its receptor mRNA in angiosarcoma. Lab Invest 1995, 73, 859-863.
101. 101. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth is a potential tumour angiogenesis factor in vivo. Nature 1992, 359, 845-847.
102. 102. Phillips HS, Armanini M, Stavrou D, Ferrara N, Westphal M. Intense focal expression of vascular endothelial growth factor mRNA in human intracranial neoplasms: association with regions of necrosis. Int J Oncol 1993, 2, 913-919.
103. 103. Berkman RA, Merrill MJ, Reinhold WC, et al. Expression of the vascular permeability/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest 1993, 91, 153-159.
104. 104. Freeman MR, Schneck FX, Gagnon ML, et al. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res 1995, 55, 4140-4145.
105. 105. Qu-Hong J, Nagy JA, Senger DR, Dvorak HF, Dvorak AM. Ultrastructural localization of VPF/VEGF to the abluminal plasma membrane and vesiculovacuolar organelles of tumor microvascular endothelium. J Histochem Cytochem 1995, 43, 381-389.
106. 106. Toi M, Hoshima S, Takayanagi T, Tominaga T. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res 1994, 85, 1045-1049.
107. 107. Maeda K, Chung YS, Ogawa Y, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996, 77, 858-863.
108. 108. Kim KJ, Li B, Houck K, Winer J, Ferrara N. The vascular endothelial growth factor proteins. Identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 1992, 7, 53-64.
109. 109. Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995, 95, 1789-1797.
110. 110. Borgström P, Hillan KJ, Sriramao P, Ferrara N. Complete inhibition of angiogenesis and growth of micro tumors by anti-VEGF neutralizing antibodies. Novel concepts of angiostatic therapy from intravital microscopy. Cancer Res 1996, 56, 4032-4039.
111. 111. Melnyk O, Schuman MA, Kim KJ. Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth. Cancer Res 1996, 56, 921-924.
112. 112. Asano M, Yukita A, Matsumoto T, Kondo S, Suzuki H. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to vascular endothelial growth factor/vascular permeability factor. Cancer Res 1995, 55, 5296-5301.
113. 113. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A. Glioblastoma growth is inhibited in vivo by a negative dominant Flk-1 mutant. Nature 1994, 367, 576-579.
114. 114. Millauer B, Longhi MP, Plate PH, Shawver LK, Risau W, Ullrich A. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 1996, 56, 1615-1620.
115. 115. Patz A, Studies on retinal neovascularization. Invest Ophthalmol Vis Sci 1980, 19, 1133-1138.
116. 116. Olk RJ, Lee CM. Diabetic Retinopathy: Practical Management. Philadelphia, J.B. Lippincott Co., 1993.
117. 117. Michaelson IC. The mode of development of the vascular system of the retina with some observations on its significance for certain retinal disorders. Trans Ophthalmol Soc UK 1948, 68, 137-180.
118. 118. Adamis AP, Miller JW, Bernal M-T, et al. Increased vascular endothelial growth factor in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994, 118, 445-450.
119. 119. Malecaze F, Clemens S, Simorer-Pinotel V, et al. Detection of vascular endothelial growth factor mRNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol 1994, 112, 1476-1482.
120. 120. Ferrara N. Vascular endothelial growth factor - The trigger for neovascularization in the eye (Editorial). Lab Invest 1995, 72, 615-618.
121. 121. Adamis AP, Shima DT, Tolentino M, et al. Inhibition of VEGF prevents retinal-ischemia associated iris neovascularization in a primate. Arch Ophthalmol 1996, 114, 66-71.
122. 122. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995, 92, 10457-10461.
123. 123. Bressler NM, Fine SL, Bressler SB. Angiographic interpretation of classic and occult choroidal neovascularization. In Lewis H, Ryan SJ, eds. Medical and Surgical Retina. St. Louis, Mosby, 1994, 3-11.
124. 124. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1996, 37, 855-868.
125. 125. Maglione D, Guerriero V, Viglietto G, Delli-Bovi P, Persico MG. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA 1991, 88, 9267-9271.
126. 126. DiSalvo J, Bayne ML, Conn G, et al. Purification and characterization of a naturally occurring vascular endothelial growth factor placenta growth factor heterodimer. J Biol Chem 1995, 270, 7717-7723.
127. 127. Pajusola K, Aprelikova O, Korhonen J, et al. FLT4 receptor tyrosine kinase contains seven immunoglublin-like loops and is expressed in multiple human tissues and cell lines. Cancer Res 1992, 52, 5738-5743.
128. 128. Kaipainanen A, Korhonen K, Mustonen V, et al. Expression of the FLT4 receptor tyrosine kinase becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA 1995, 92, 3566-3570.
129. 129. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the FLT4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996, 15, 290-298.
130. 130. Lee J, Gray A, Yuan J, Luoh S-M, Avraham H, Wood WI. Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc Natl Acad Sci USA 1996, 93, 1988-1992.
131. 131. Olofsson B, Pajusola K, Kaipaineen A, et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA 1996, 93, 2576-2581.
132. 132. Lyttle DJ, Fraser KM, Flemings SB, Mercer AA, Robinson AJ. Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus. J Virol 1994, 68, 84-92.